Coya Therapeutics Files 2024 Annual Report Amendment
Ticker: COYA · Form: 10-K/A · Filed: Apr 28, 2025 · CIK: 1835022
| Field | Detail |
|---|---|
| Company | Coya Therapeutics, Inc. (COYA) |
| Form Type | 10-K/A |
| Filed Date | Apr 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, annual-report, governance
TL;DR
Coya Therapeutics filed its amended 2024 10-K, check for updates on awards and executive roles.
AI Summary
Coya Therapeutics, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing includes information related to awards granted to individuals, including Dr. Arun Swaminathan, while he served as Chief Business Officer. The company is incorporated in Delaware and its stock is listed under the SEC file number 001-41583.
Why It Matters
This amendment provides updated or corrected information for Coya Therapeutics' 2024 fiscal year, which could impact investor understanding of the company's financial health and governance.
Risk Assessment
Risk Level: medium — As a 10-K/A filing, it indicates potential corrections or additions to previously filed information, which could signal underlying issues or changes in reporting.
Key Numbers
- 001-41583 — SEC File Number (Identifies Coya Therapeutics, Inc. in SEC filings.)
- 2024-12-31 — Fiscal Year End (The period covered by the annual report.)
Key Players & Entities
- Coya Therapeutics, Inc. (company) — Registrant
- Dr. Arun Swaminathan (person) — Chief Business Officer at time of award
- 001-41583 (company) — SEC File Number
- 2024-12-31 (date) — Fiscal Year End
- 20250428 (date) — Filing Date
FAQ
What specific awards were granted to Dr. Arun Swaminathan?
The filing mentions an award granted while Dr. Swaminathan served as Chief Business Officer, but the specific details of the award are not provided in this excerpt.
What is the purpose of this 10-K/A filing?
This is an amendment to the annual report (10-K) for the fiscal year ended December 31, 2024, indicating that previously filed information may be updated or corrected.
When was this amendment filed with the SEC?
The filing was made on April 28, 2025.
What is Coya Therapeutics, Inc.'s primary business?
Coya Therapeutics, Inc. is classified under Pharmaceutical Preparations (SIC code 2834).
Where is Coya Therapeutics, Inc. headquartered?
The company's business address is located at 12645 Memorial Dr., Suite F1 #305, Houston, TX 77024.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 28, 2025 by Dr. Arun Swaminathan regarding Coya Therapeutics, Inc. (COYA).